FDA has held a key review meeting on ivonescimab after the company received a complete response letter (CRL), according to a BIOCENTURY report. The discussion centered on whether additional follow-up could address unanswered questions about the drug’s activity in Western patients after earlier analyses fell short in EGFR-mutant non-small cell lung cancer.
Get the Daily Brief